Related Experiment Video
Updated: May 18, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer
Yuwen Xue1, Hening Ren, Wei Xiao
1Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, PR China.
Abstract:
AZ64 is a novel antitumor agent designed as a tropomyosin-related kinase (Trk) inhibitor; however, its effect on lung cancer and its mechanism of action remain unclear. This study aimed to elucidate the antitumor activity of AZ64 and its mechanism of action against non-small cell lung cancer (NSCLC). Our results demonstrate that AZ64 has a potent anti-proliferative effect on NSCLC cells and acts in a dose- and time-dependent manner. We also demonstrate that AZ64 suppresses the anchorage-independent growth and invasion of NSCLC cells. In vivo experiments demonstrated that AZ64 significantly reduced the tumor growth of NSCLC xenografts in nude mice and was well-tolerated. Mechanistic experiments revealed that AZ64 induced the G2/M arrest of NSCLC cells by the accumulation of phospho-cdc2 (Tyr15) at the G2/M transition, following the downregulation of Cdc25C expression. Collectively, our data demonstrate that AZ64 is a potential antitumor drug that may be used for the treatment of NSCLC, which functions by targeting the G2/M transition via the inhibition of the dephosphorylation of phospho-cdc2 (Tyr15).
Insights
AZ64, a novel tropomyosin-related kinase (Trk) inhibitor, effectively inhibits non-small cell lung cancer (NSCLC) proliferation and tumor growth. It induces cell cycle arrest by targeting the G2/M transition, showing potential as an NSCLC therapeutic.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
- Tropomyosin-related kinase (Trk) inhibitors are emerging as targeted therapies for various cancers.
- The specific antitumor activity and mechanism of AZ64 in NSCLC were previously undefined.
Purpose of the Study:
- To investigate the antitumor efficacy of AZ64 against NSCLC.
- To elucidate the underlying molecular mechanism of AZ64's action in NSCLC.
- To evaluate AZ64's therapeutic potential for NSCLC treatment.
Main Methods:
- In vitro assays assessing cell proliferation, anchorage-independent growth, and invasion of NSCLC cells treated with AZ64.
- In vivo studies using NSCLC xenograft models in nude mice to evaluate tumor growth inhibition and tolerability.
- Mechanistic studies analyzing cell cycle progression, including G2/M arrest and key protein expression (phospho-cdc2, Cdc25C).
Main Results:
- AZ64 demonstrated potent, dose- and time-dependent anti-proliferative effects on NSCLC cells.
- AZ64 significantly suppressed anchorage-independent growth and invasion of NSCLC cells.
- In vivo, AZ64 markedly reduced NSCLC xenograft tumor growth with good tolerability.
- Mechanistically, AZ64 induced G2/M cell cycle arrest by increasing phospho-cdc2 (Tyr15) and downregulating Cdc25C.
Conclusions:
- AZ64 exhibits significant antitumor activity against NSCLC in vitro and in vivo.
- AZ64 functions by inducing G2/M cell cycle arrest through specific molecular targets.
- AZ64 represents a promising therapeutic candidate for the treatment of non-small cell lung cancer.
